Other biomarkers for diagnosis and prognosis of PCa, like PCA3 [9,10,11], miR-375 [12,13], urokinase-typ plasminogen activator receptor (uPAR) [14,15], or combinations of biomarkers [16,17], are controversially discussed in the literature, with limited impact on the actual clinical management of PCa so far. This evidence concerns the gene PCA3 and posterior cortical atrophy.